checkAd

Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib

Concurrent $100 million equity offering

Naporafenib has a potential first-in-class and best-in-class profile in multiple RAS/MAPK pathway-driven tumors

Pivotal-ready asset has been dosed in over 500 patients to date and expands Erasca’s addressable population

Erasca to host conference call and webcast today at 8:30 am ET

SAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced it has entered into an exclusive worldwide license agreement with Novartis (NYSE: NVS) for naporafenib, a Phase 2 pivotal-ready pan-RAF inhibitor with a potential first-in-class and best-in-class profile in NRAS mutant (NRASm) melanoma and other RAS/MAPK pathway-driven tumors. To date, naporafenib has been dosed in over 500 patients across multiple trials and has demonstrated preliminary clinical proof-of-concept as well as favorable safety and tolerability data both as a single agent and in combination with other molecularly targeted and immuno-oncology therapies.

As separately announced, Erasca has priced a $100 million equity offering with select healthcare investors.

“Naporafenib aligns with our mission by expanding our addressable patient population and is a perfect strategic fit for Erasca based on its strong synergy with our pipeline,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “This Phase 2 pivotal-ready molecule with favorable clinical safety, tolerability, and proof-of-concept data significantly accelerates our transition into a late-stage development company, bringing us closer to realizing our aspiration of delivering novel cancer therapies to patients in need. This license, coupled with our simultaneous financing from leading healthcare investors, solidifies our leadership in advancing treatments for RAS/MAPK pathway-driven cancers.”

Naporafenib (LXH254) is a potent and selective inhibitor of BRAF and CRAF, with a potential first-in-class and best-in-class profile. Safety, tolerability, and preliminary proof of concept of naporafenib alone or in combination have been shown in over 500 patients treated to date in NRASm melanoma and other RAS/MAPK pathway-driven tumors. Erasca plans to initially focus on advancing and securing potential regulatory approval for naporafenib plus trametinib (MEKINIST) in RAS Q61X tissue agnostic solid tumors as part of the planned Phase 2 SEACRAFT-1 trial and NRASm melanoma as part of the planned Phase 3 SEACRAFT-2 trial.

Seite 1 von 3



0 Kommentare
Nachrichtenquelle: globenewswire
 |  118   |   |   

Schreibe Deinen Kommentar

Disclaimer

Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib Concurrent $100 million equity offering Naporafenib has a potential first-in-class and best-in-class profile in multiple RAS/MAPK pathway-driven tumors Pivotal-ready asset has been dosed in over 500 patients to date and expands Erasca’s …

Nachrichten des Autors

360 Leser
324 Leser
324 Leser
312 Leser
300 Leser
288 Leser
280 Leser
268 Leser
268 Leser
264 Leser
4016 Leser
640 Leser
552 Leser
508 Leser
504 Leser
468 Leser
464 Leser
456 Leser
436 Leser
424 Leser
4016 Leser
1684 Leser
1172 Leser
1132 Leser
956 Leser
840 Leser
828 Leser
820 Leser
804 Leser
800 Leser
10593 Leser
4428 Leser
4016 Leser
3488 Leser
2744 Leser
2294 Leser
2246 Leser
2077 Leser
2072 Leser
2037 Leser